ストックスクリーナーアプリを入手
2.50
17.37%
0.37
アフターアワーズ：
2.41
-0.09
-3.60%
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus
CytomX Therapeutics Reports Q1 2025 Results and Progress - TipRanks
CytomX Therapeutics: Q1 Earnings Snapshot - MySA
CytomX Therapeutics Inc earnings beat by $0.21, revenue topped estimates - Investing.com South Africa
Transcript : CytomX Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock - Latham & Watkins LLP
CytomX Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CytomX Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CTMX) - Seeking Alpha
CytomX shares priced at $1.30 in $100 million offering By Investing.com - Investing.com South Africa
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga
CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data - marketscreener.com
Earnings call transcript: CytomX Therapeutics Q1 2025 earnings beat expectations - Investing.com
Earnings call transcript: CytomX Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com India
CytomX Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
CytomX Therapeutics shares soar on positive cancer drug data - Investing.com Australia
CytomX Therapeutics (CTMX) Rises on $100M Offering and Positive Study Results - GuruFocus
Is CytomX Therapeutics Inc (NASDAQ: CTMX) A Great Stock To Invest In? - Stocksregister
Cytomx Announces Positive Interim Data From Phase 1 Dose Escalation Study Of Epcam Antibody Drug Conjugate (Cx-2051) Candidate In Patients With Advanced Colorectal Cancer (Crc) - marketscreener.com
CytomX Therapeutics reports Q1 EPS 27c, consensus 13c - TipRanks
CytomX Therapeutics Announces Pricing of $100 Million Underwritt - GuruFocus
CytomX shares priced at $1.30 in $100 million offering - Investing.com Australia
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings: Revenue Surges to $50.9 Million, Beating Estimates - GuruFocus
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering (CTMX:NASDAQ) - Seeking Alpha
CytomX (CTMX) Surpasses Earnings and Revenue Expectations - GuruFocus
CytomX Therapeutics (CTMX) Reports Promising Phase 1 Results for CX-2051 in CRC | CTMX Stock News - GuruFocus
CytomX Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - The Manila Times
CytomX Therapeutics Reports Positive Interim Phase 1 Data - TipRanks
CytomX Announces Positive Interim Data From Phase 1 Dose Escalat - GuruFocus
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
CytomX Therapeutics, Inc. SEC 10-Q Report - TradingView
CytomX Therapeutics Reports Promising Interim Phase 1 Data for CX-2051 in Advanced Colorectal Cancer with Plans for Phase 2 Study Initiation - Nasdaq
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody - Bluefield Daily Telegraph
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - The Globe and Mail
CTMX stock touches 52-week low at $0.76 amid market challenges - MSN
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Monday - Defense World
CytomX (CTMX) Prepares for Q1 Earnings Announcement - GuruFocus
CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For - Yahoo Finance
Insider’s View: Deciphering CytomX Therapeutics Inc (CTMX)’s Financial Health Through Ratios - DWinneX
CytomX Therapeutics to Report First Quarter 2025 Financial Resul - GuruFocus
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 | CTMX Stock News - GuruFocus
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 - The Manila Times
Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors - Stock Titan
CytomX Therapeutics Inc expected to post earnings of 12 cents a shareEarnings Preview - TradingView
CytomX Therapeutics Inc [CTMX] Stock sold by Insider McCarthy Sean A. for $22556.0 - knoxdaily.com
Get in on CytomX Therapeutics Inc’s (CTMX) buy-in window today! - Sete News
Taiwan Semiconductor Is Navigating Unprecedented Circumstances Effectively - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Observations on the CytomX Therapeutics Inc (NASDAQ:CTMX) Growth Curve - uspostnews.com
Market Update: CytomX Therapeutics Inc (CTMX) Sees Negative Movement, Closing at 0.71 - DWinneX
Renaissance Technologies LLC Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX and Moderna unveil promising cancer therapy data By Investing.com - Investing.com Canada
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by JPMorgan Chase & Co. - Defense World
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - ADVFN
Cytomx Therapeutics Presents Preclinical Data For mRNA Encoded Masked Il-12 Molecule In Collaboration With Moderna - marketscreener.com
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting - The Manila Times
3.01%
大文字化:
|
ボリューム (24 時間):